TAXUS V sub-population data further support efficacy of TAXUS(R) Express(2)(TM) stent system in diabetic patients
25 Mai 2005 - 1:05PM
PR Newswire (US)
TAXUS V sub-population data further support efficacy of TAXUS(R)
Express(2)(TM) stent system in diabetic patients VANCOUVER and
PARIS, France, May 25 /PRNewswire-FirstCall/ -- Angiotech
Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP) corporate
partner, Boston Scientific ("BSC"), today announced nine-month
sub-population data from its TAXUS V clinical trial that further
supports the efficacy of the TAXUS(R) Express(2)(TM) paclitaxel-
eluting coronary stent system for the treatment of coronary artery
disease in diabetic patients. TAXUS V expands on the TAXUS IV
pivotal trial by studying the most challenging lesions and
highest-risk patients ever studied in a randomized, controlled
clinical trial in the United States. The data were presented by
Gregg W. Stone, M.D., the study's Principal Investigator and
Professor of Medicine, Columbia University Medical Center in New
York. BSC made the announcement at the annual Paris Course on
Revascularization. "The diabetic sub-population data reinforce the
overall positive findings of the TAXUS V study, which has
significantly expanded our understanding of the efficacy of the
TAXUS paclitaxel-eluting system in very complex patients," said Dr.
Stone. "These results confirm that the TAXUS technology is an
effective tool for clinicians to use in treating challenging cases
such as diabetics. This data will be welcomed by interventional
cardiologists who treat these difficult patients." BSC reported
that the diabetic sub-population analysis demonstrated significant
improvements among diabetic patients receiving the TAXUS system
versus those in the control group. Diabetic patients represent
approximately 31 percent (356 of 1,156) of the overall patient
population in the study. Diabetic patients are more likely than
non-diabetic patients to experience restenosis following
angioplasty and stenting with bare metal stents, and may stand to
benefit substantially from drug-eluting stent technology. The
nine-month target lesion revascularization rate (TLR, or
retreatment rate) for the medically treated diabetic sub-population
of the TAXUS group was 9.6 percent compared with 17.5 percent in
the control group (P(equal sign)0.09). The diabetic sub-population
also reported an in-segment binary restenosis rate of 18.2 percent
in the TAXUS group compared with 38.4 percent in the control group
(P less than 0.0001). In addition to the improved restenosis rates,
marked improvement in in-segment late loss was also seen in the
diabetic sub-population of the TAXUS group compared to the control
group (0.31 (+/-0.56) mm versus 0.62 (+/-0.61) mm; P less than
0.0001). TAXUS V is a randomized, double-blinded trial that
enrolled 1,172 patients at 66 sites in the United States, assessing
the safety and efficacy of a slow-release formulation
paclitaxel-eluting coronary stent system in reducing restenosis in
de novo lesions 10 - 46 mm in length and 2.25 - 4.0 mm in diameter.
BSC previously announced in March that the trial met its primary
endpoint of nine-month target vessel revascularization
(symptom-driven repeat revascularization of the target vessel, or
TVR), as well as all secondary endpoints. BSC acquired worldwide
exclusive rights from Angiotech to use paclitaxel to coat its
coronary stent products and has co-exclusive rights to other
vascular and non-vascular products. Vancouver-based Angiotech
Pharmaceuticals, Inc. is a specialty pharmaceutical company
pioneering the combination of pharmaceutical compounds with medical
devices and biomaterials to both create novel solutions for poorly
addressed disease states and dramatically improve surgical
outcomes. To find out more about Angiotech Pharmaceuticals, Inc.
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at
http://www.angiotech.com/. Statements contained herein that are not
based on historical or current fact, including without limitation
statements containing the words "anticipates," "believes," "may,"
"continue," "estimate," "expects," "may" and "will" and words of
similar import, constitute "forward-looking statements" within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995. Such forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause the actual
results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, among others, the
following: general economic and business conditions, both
nationally and in the regions in which the Company operates;
technology changes; competition; changes in business strategy or
development plans; the ability to attract and retain qualified
personnel; existing governmental regulations and changes in, or the
failure to comply with, governmental regulations; liability and
other claims asserted against the Company; and other factors
referenced in the Company's filings with the United States
Securities and Exchange Commission or the Canadian securities
regulators. Given these uncertainties, readers are cautioned not to
place undue reliance on such forward-looking statements. The
Company does not assume the obligation to update any
forward-looking statements. CONTACTS: Todd Young, Angiotech
Pharmaceuticals (Analysts & Investors) (604) 221-7676 ext 6933
Rui Avelar, Angiotech Pharmaceuticals, Inc. (Analysts) (604)
221-7676 ext 6996 Eric Starkman, Starkman & Associates (Media),
(212) 252-8545 ext 12 DATASOURCE: Angiotech Pharmaceuticals, Inc.
CONTACT: Todd Young, Angiotech Pharmaceuticals (Analysts &
Investors), (604) 221-7676 ext 6933; Rui Avelar, Angiotech
Pharmaceuticals, Inc. (Analysts), (604) 221-7676 ext 6996; Eric
Starkman, Starkman & Associates (Media), (212) 252-8545 ext 12
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024